FDA's Final Approval of Generic and Market Entry

The U.S. Food and Drug Administration (FDA) has granted final approval for Umedica Laboratories' generic version of Sacubitril/Valsartan, a combination drug for heart failure (Abbreviated New Drug Application, ANDA 219946), on August 3, 2026. This approval is part of the generic competition following the expiration of the patent for the original drug, Entresto, from Novartis. The entry of the generic into the market is expected to alleviate the financial burden on heart failure patients and improve the efficiency of the U.S. healthcare system. Umedica will significantly expand its portfolio in the U.S., the world's largest pharmaceutical market, through this approval.

Entresto's Patent Cliff and Revenue Impact

The original drug, Entresto, is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). In 2024, the drug generated global annual sales of $7.8 billion, making it a key revenue driver for Novartis. However, with the expiration of its U.S. market exclusivity in 2025, generic competition began, leading to a sharp decline in sales. As of the second quarter of 2026, Entresto's U.S. sales have fallen by approximately 50% year-over-year due to generic penetration, demonstrating the patent cliff phenomenon.

Intensifying Competition in the Generic Market

Umedica's ANDA approval is expected to further intensify price competition in the market. Several global generic pharmaceutical companies, including Lupin, MSN Laboratories, and Hetero, have already obtained approval for sacubitril/valsartan generics and are either entering or preparing to enter the market. Umedica aims to secure a competitive advantage in manufacturing costs through vertical integration with its active pharmaceutical ingredient (API) manufacturing subsidiary, Amoli Organics. With the simultaneous entry of multiple competitors, a rapid decline in prices and a battle for market share are inevitable.

Resolution of Litigation Risks and Commercialization Prospects

Novartis has been defending against generic entry by filing patent infringement lawsuits against Umedica and other generic developers. However, the lawsuit against Umedica was recently withdrawn, significantly reducing regulatory and legal uncertainties. Umedica will now collaborate with its U.S. partners to enter the commercialization phase. Leveraging the high brand recognition of the original drug, Umedica plans to minimize marketing costs and rapidly increase its prescription share through listing with pharmacy benefit managers (PBMs).